The European Investment Bank (EIB) will provide Anaconda Biomed, the medical device start-up and CataloniaBio & HelathTech member, with venture debt funding of up to €10 million to support the development of its second generation of catheter for the treatment of acute ischemic stroke (AIS). This is the second venture debt operation in Spain backed by European Guarantee Fund (EGF) — part of the €540 billion EU response to the economic impact of COVID-19.
The EIB will provide long-term funding at favourable rates with flexible repayment. This will enable Anaconda Biomed to test the next generation of catheters to improve endovascular treatment for patients suffering from ischemic stroke, thus reducing disability and mortality rates. In concrete terms, the EU bank’s support will allow Anaconda Biomed to finalise development and the regulatory path to validation of the treatment by both the European Medicines Agency (EMA) and the Food & Drug Administration in the United States.
Anaconda Biomed S.L. is a medical technology company dedicated to developing next generation thrombectomy systems for the treatment of ischemic stroke. Its flagship product is the Advanced Neurovascular Access (ANA) device.
You may also be interested in:
Comments